Feng, Guowen Zhou, Xiaodan Chen, Jia Li, Dan Chen, Li
Published in
Frontiers in Oncology
Background With the widespread application of platinum drugs in antitumor therapy, the incidence of platinum drug adverse events (ADEs) is always severe. This study aimed to explore the adverse event signals of Cisplatin, Carboplatin and Oxaliplatin, three widely used platinum-containing drugs, and to provide a reference for rational individualized...
Yan, Le Ren, Bi Hu, Rongqiu Zhang, Huiping Gou, Haocheng
Published in
Frontiers in Pharmacology
Objective: For metastatic/recurrent nasopharyngeal carcinoma (NPC) patients, a programmed cell death protein 1 (PD-1) is a controversial option. This meta-analysis aimed to investigate the efficacy and safety of PD-1 inhibitors in patients with metastatic/recurrent NPC. Methods: Electronic databases such as PubMed, Embase, Cochrane library, and Web...
Mora, Jaume Chan, Godfrey C Morgenstern, Daniel A Nysom, Karsten Bear, Melissa K Tornøe, Karen Kushner, Brian H
Published in
Cancer reports (Hoboken, N.J.)
Naxitamab is a humanized GD2-binding monoclonal antibody that received accelerated approval from the U.S. Food and Drug Administration for refractory or relapsed high-risk neuroblastoma limited to bone or bone marrow. Trial 201 (NCT03363373) is an ongoing global clinical trial to evaluate the efficacy and safety of naxitamab in combination with gra...
Bareiß, Alan Uzun, Günalp Mikus, Marco Becker, Matthias Althaus, Karina Schneiderhan-Marra, Nicole Fürstberger, Axel Schwab, Julian D Kestler, Hans A Holderried, Martin
...
Published in
Viruses
As the Corona Disease 2019 (COVID-19) caused by SARS-CoV-2 persists, vaccination is one of the key measures to contain the spread. Side effects (SE) from vaccination are one of the reasons for reluctance to vaccinate. We systematically investigated self-reported SE after the first, second, and booster vaccinations. The data were collected during th...
Yamasaki, Tomoaki Sakata, Yuhei Suekane, Takehisa Nebiki, Hiroko
Published in
Internal medicine (Tokyo, Japan)
Neuville, Carole Aubin, François Puzenat, Eve Popescu, Dragos Crepin, Thomas Nardin, Charlée
Published in
Frontiers in Oncology
Introduction Adverse events (AEs) of immune checkpoint inhibitors (ICIs) are frequent and mainly due to an overactivity of the immune system leading to excessive inflammatory responses (immune-related AE) that can affect any organ of the body. Beside the most frequent AEs, there are rare AEs whose diagnosis and treatment can be challenging. We repo...
Lee, Sang-Doo Ahn, Hye-Jin Shin, Min Kyung
Published in
JAAD case reports
Shorey, Shefaly Wong, Phyllis Zhi En
Published in
Trauma, violence & abuse
Health care providers are often "second victims" of traumatic childbirth events and should be adequately supported by their organizations to alleviate occupational stress and burnout. Therefore, this review aimed to explore and understand the vicarious traumatic childbirth experiences of health care providers, including obstetricians, midwives, nur...
Yalcin, Nadir; Kasikci, Merve; Celik, Hasan Tolga; Allegaert, Karel; 46648; Demirkan, Kutay; Yigit, Sule; Yurdakok, Murat;
BACKGROUND: Critically ill neonates are at greater risk for adverse drug reactions (ADRs). The differentiation of ADRs from reactions associated with organ dysfunction/immaturity or genetic variability is difficult. METHODS: In this prospective cohort study, each ADR was assessed using newborn-specific severity and probability scales by the clinica...
Jiang, Tingting Su, Hui Li, Yanping Wu, Yuanlin Ming, Yue Li, Chen Fu, Ruoqiu Feng, Lu Li, Ziwei Li, Li
...
Published in
Frontiers in Pharmacology
Objective: In recent years, the emergence of immunomodulatory drugs (IMiDs) has significantly improved clinical outcomes in patients with multiple myeloma (MM); however, serious adverse events (AEs) have hindered their safe clinical application. This study aimed to characterize the safety profiles and differences in IMiDs through a disproportionali...
